

# Barbara Bedogni

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3132743/publications.pdf>

Version: 2024-02-01

23  
papers

1,045  
citations

471509

17  
h-index

642732

23  
g-index

23  
all docs

23  
docs citations

23  
times ranked

1844  
citing authors

#	ARTICLE	IF	CITATIONS
1	The biology of human hair greying. <i>Biological Reviews</i> , 2021, 96, 107-128.	10.4	64
2	Wound Healing Assay for Melanoma Cell Migration. <i>Methods in Molecular Biology</i> , 2021, 2265, 65-71.	0.9	19
3	MT1-MMP-dependent ECM processing regulates laminB1 stability and mediates replication fork restart. <i>PLoS ONE</i> , 2021, 16, e0253062.	2.5	3
4	Blockade of CCR5 in melanoma: An alternative immune checkpoint modulator. <i>Experimental Dermatology</i> , 2020, 29, 196-196.	2.9	5
5	Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 6039-6050.	7.0	24
6	Hair(y) Matters in Melanoma Biology. <i>Trends in Molecular Medicine</i> , 2020, 26, 441-449.	6.7	7
7	ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin. <i>Cancers</i> , 2019, 11, 1425.	3.7	22
8	The membrane tethered matrix metalloproteinase MT1-MMP triggers an outside-in DNA damage response that impacts chemo- and radiotherapy responses of breast cancer. <i>Cancer Letters</i> , 2019, 443, 115-124.	7.2	16
9	Inhibiting Notch1 enhances immunotherapy efficacy in melanoma by preventing Notch1 dependent immune suppressive properties. <i>Cancer Letters</i> , 2018, 434, 144-151.	7.2	25
10	The natural compound fucoidan from New Zealand <i>Undaria pinnatifida</i> synergizes with the ERBB inhibitor lapatinib enhancing melanoma growth inhibition. <i>Oncotarget</i> , 2017, 8, 17887-17896.	1.8	26
11	Synchronized Targeting of Notch and ERBB Signaling Suppresses Melanoma Tumor Growth through Inhibition of Notch1 and ERBB3. <i>Journal of Investigative Dermatology</i> , 2016, 136, 464-472.	0.7	30
12	The membrane tethered matrix metalloproteinase MT1-MMP at the forefront of melanoma cell invasion and metastasis. <i>Pharmacological Research</i> , 2016, 111, 17-22.	7.1	53
13	The thiirane-based selective MT1-MMP/MMP2 inhibitor ND-322 reduces melanoma tumor growth and delays metastatic dissemination. <i>Pharmacological Research</i> , 2016, 113, 515-520.	7.1	27
14	Cellular Prion Protein Mediates Pancreatic Cancer Cell Survival and Invasion through Association with and Enhanced Signaling of Notch1. <i>American Journal of Pathology</i> , 2016, 186, 2945-2956.	3.8	21
15	Notch1 Autoactivation via Transcriptional Regulation of Furin, Which Sustains Notch1 Signaling by Processing Notch1-Activating Proteases ADAM10 and Membrane Type 1 Matrix Metalloproteinase. <i>Molecular and Cellular Biology</i> , 2015, 35, 3622-3632.	2.3	34
16	MT1-MMP dependent repression of the tumor suppressor SPRY4 contributes to MT1-MMP driven melanoma cell motility. <i>Oncotarget</i> , 2015, 6, 33512-33522.	1.8	17
17	MT1-MMP modulates melanoma cell dissemination and metastasis through activation of MMP2 and RAC1. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 287-296.	3.3	53
18	Notch signaling in melanoma: interacting pathways and stromal influences that enhance Notch targeting. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 162-168.	3.3	35

#	ARTICLE	IF	CITATIONS
19	Noncanonical Activation of Notch1 Protein by Membrane Type 1 Matrix Metalloproteinase (MT1-MMP) Controls Melanoma Cell Proliferation. <i>Journal of Biological Chemistry</i> , 2014, 289, 8442-8449.	3.4	28
20	Hypoxia, melanocytes and melanoma " survival and tumor development in the permissive microenvironment of the skin. <i>Pigment Cell and Melanoma Research</i> , 2009, 22, 166-174.	3.3	111
21	Notch1 is an effector of Akt and hypoxia in melanoma development. <i>Journal of Clinical Investigation</i> , 2008, 118, 3660-3670.	8.2	187
22	The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. <i>Cancer Cell</i> , 2005, 8, 443-454.	16.8	164
23	Topical Treatment with Inhibitors of the Phosphatidylinositol 3-Kinase/Akt and Raf/Mitogen-Activated Protein Kinase Kinase/Extracellular Signal-Regulated Kinase Pathways Reduces Melanoma Development in Severe Combined Immunodeficient Mice. <i>Cancer Research</i> , 2004, 64, 2552-2560.	0.9	74